Takeda Pharmaceutical Co. said Tuesday that it expects to incur a consolidated net loss of 383 billion yen in fiscal 2019 to next March, compared with the 109,126-million-yen net profit in the previous year.
The bottom line will be dented by 796 billion yen due to an accounting factor related to the Japanese drug maker's 6.2-trillion-yen acquisition of major Irish peer Shire PLC in January. Specifically, Takeda reevaluated inventories at Shire at market value.
(c) 2019 TehranTimes. All Rights Reserved. Provided by SyndiGate Media Inc. (Syndigate.info)., source Middle East & North African Newspapers